These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19477910)

  • 41. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells.
    D'Agati V; Yan SF; Ramasamy R; Schmidt AM
    Trends Endocrinol Metab; 2010 Jan; 21(1):50-6. PubMed ID: 19783154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms.
    Sterenczak KA; Willenbrock S; Barann M; Klemke M; Soller JT; Eberle N; Nolte I; Bullerdiek J; Murua Escobar H
    Gene; 2009 Apr; 434(1-2):35-42. PubMed ID: 19061941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response.
    Buetler TM; Leclerc E; Baumeyer A; Latado H; Newell J; Adolfsson O; Parisod V; Richoz J; Maurer S; Foata F; Piguet D; Junod S; Heizmann CW; Delatour T
    Mol Nutr Food Res; 2008 Mar; 52(3):370-8. PubMed ID: 18320574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of the S100A6 mutant (C3S) with the V domain of the receptor for advanced glycation end products (RAGE).
    Mohan SK; Gupta AA; Yu C
    Biochem Biophys Res Commun; 2013 May; 434(2):328-33. PubMed ID: 23537648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus.
    Peng WH; Lu L; Wang LJ; Yan XX; Chen QJ; Zhang Q; Zhang RY; Shen WF
    Arch Med Res; 2009 Jul; 40(5):393-8. PubMed ID: 19766904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RAGE in tissue homeostasis, repair and regeneration.
    Sorci G; Riuzzi F; Giambanco I; Donato R
    Biochim Biophys Acta; 2013 Jan; 1833(1):101-9. PubMed ID: 23103427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot study.
    Hájek Z; Germanová A; Koucký M; Zima T; Kopecký P; Vítkova M; Parízek A; Kalousová M
    J Perinat Med; 2008; 36(5):399-404. PubMed ID: 18771410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RAGE and its ligands: a lasting memory in diabetic complications?
    Yan SF; Ramasamy R; Bucciarelli LG; Wendt T; Lee LK; Hudson BI; Stern DM; Lalla E; DU Yan S; Rong LL; Naka Y; Schmidt AM
    Diab Vasc Dis Res; 2004 May; 1(1):10-20. PubMed ID: 16305050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alternative splicing of RAGE: roles in biology and disease.
    Kalea AZ; Schmidt AM; Hudson BI
    Front Biosci (Landmark Ed); 2011 Jun; 16(7):2756-70. PubMed ID: 21622207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RAGE-mediated cell signaling.
    Rouhiainen A; Kuja-Panula J; Tumova S; Rauvala H
    Methods Mol Biol; 2013; 963():239-63. PubMed ID: 23296615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.
    Tanikawa T; Okada Y; Tanikawa R; Tanaka Y
    J Vasc Res; 2009; 46(6):572-80. PubMed ID: 19571577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Soluble RAGE: a hot new biomarker for the hot joint?
    Moser B; Hudson BI; Schmidt AM
    Arthritis Res Ther; 2005; 7(4):142-4. PubMed ID: 15987496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
    Geroldi D; Falcone C; Emanuele E
    Curr Med Chem; 2006; 13(17):1971-8. PubMed ID: 16842191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1.
    Rai V; Maldonado AY; Burz DS; Reverdatto S; Yan SF; Schmidt AM; Shekhtman A
    J Biol Chem; 2012 Feb; 287(7):5133-44. PubMed ID: 22194616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Up-regulation in receptor for advanced glycation end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro.
    Yoshida T; Park JS; Yokosuka K; Jimbo K; Yamada K; Sato K; Takeuchi M; Yamagishi S; Nagata K
    Spine (Phila Pa 1976); 2009 Jul; 34(15):1544-8. PubMed ID: 19564763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification, classification, and expression of RAGE gene splice variants.
    Hudson BI; Carter AM; Harja E; Kalea AZ; Arriero M; Yang H; Grant PJ; Schmidt AM
    FASEB J; 2008 May; 22(5):1572-80. PubMed ID: 18089847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The structure and function of RAGE].
    Zhao SC; Hou FF; Jiang Y
    Sheng Li Ke Xue Jin Zhan; 2003 Jan; 34(1):71-3. PubMed ID: 12778817
    [No Abstract]   [Full Text] [Related]  

  • 58. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.
    Yan SF; Ramasamy R; Schmidt AM
    Biochem Pharmacol; 2010 May; 79(10):1379-86. PubMed ID: 20096667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The immunobiology of the receptor of advanced glycation end-products: trends and challenges.
    González I; Romero J; Rodríguez BL; Pérez-Castro R; Rojas A
    Immunobiology; 2013 May; 218(5):790-7. PubMed ID: 23182709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions.
    Perrone L; Devi TS; Hosoya K; Terasaki T; Singh LP
    J Cell Physiol; 2009 Oct; 221(1):262-72. PubMed ID: 19562690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.